Please login to the form below

Not currently logged in
Email:
Password:

Chimerix hit as lead drug brincidofovir flunks trial

Antiviral failed to meet its objectives in late-stage study

ChimerixShares in US biopharma company Chimerix lost three quarter of their value after it revealed a late-stage study of antiviral drug brincidofovir failed to meet its objectives.

The phase III trial of the drug - a treatment for cytomegalovirus (CMV) infections in people undergoing stem cell transplants to repopulate bone marrow - was unable to show a significant reduction in infections in the 24 weeks after the transplant procedure.

Chimerix said it was determined to press on with the drug's development, however, saying it believes there is still a "viable path forward" for the nucleotide analogue.

Brincidofovir appeared to protect patients from infections during the first 10 weeks of the SUPPRESS study, where it was being administered as an oral therapy once-daily, outperforming placebo during this period. 

After treatment stopped however there was a higher level of infections in the brincidofovir group, negating its earlier advantage. 

Patients in the brincidofovir arm also showed an increase in mortality compared to the control arm, but the increase was not statistically significant, according to Chimerix.

In a statement, Chimerix said preliminary suggestions are that the disappointing performance was linked to confirmed cases of graft-versus-host-disease (GVHD) - when the transplanted immune cells start to attack the patient. These resulted in a significantly higher use of corticosteroids in the brincidofovir group compared to the control arm. 

"Both GVHD and use of corticosteroids are risk factors for 'late' CMV infection that occurs after discontinuation of the antiviral," said Chimerix.

The company now plans to discuss the data with the FDA and other regulatory authorities as it works out the best way to proceed with the brincidofovir programme, but for the time being has halted enrolment of the drug in two other trials involving kidney transplant patients.

It said it is continuing to carry out trials of the drug in the treatment of adenovirus and smallpox "as well as use in other populations in need of a novel compound for DNA viral infections". It has also been tested as an Ebola treatment.

Despite the brave face, it is clear that the trial failure is a big blow to the company, as brincidofovir had been predicted by some analysts to clear in excess of $2bn in annual sales at peak.

Brincidofocvir's failure in the stem cell transplant cell trial could hand an opportunity for Astellas and Vical, which are developing a DNA-based vaccine against CMV - called ASP0113 - for use in this setting.

Article by
Phil Taylor

4th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WCG

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

Sharing our insights from the eyeforpharma, Barcelona 2016 patient track
A year on from the 'launch' of patient-centricity as a key theme at eyeforpharma and how have things progressed?...
An effective commercial model for cancer care
Patient-centric cancer care...
Blog_icon_understanding-the-adoption-ladder-in-closed-loop-marketing.png
Flexible content checklist – five questions to ask
To ensure that your content gets used by local markets and has a real impact, consider these questions when commissioning or developing core materials....

Infographics